An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

The telehealth company Ro, which in the past offered compounded tirzepatide, in December announced it would be offering single-dose vials of Zepbound to patients with obesity. (It comes at a lower ...

Stimulant medications are considered the first-line treatment for ADHD for some very good reasons. Here are 6 things to know about stimulant medications in ADHD. Attention Deficit Hyperactivity ...

In the obesity space, Novo Nordisk reported data from a Phase III trial showing that a high dose of Wegovy elicited more weight loss than the approved regimen—but still fell short of results posted by ...

TUESDAY, Jan. 21, 2025 (HealthDay News) -- Popular GLP-1 medications for weight loss and diabetes may have unexpected benefits for reducing risks for conditions such as substance abuse, psychosis, ...

The company has also taken strategic steps to improve access; the company has launched a single-dose 2.5 mg and 5 mg Zepbound vials in the ... investors and individual investors who may not ...

About 140,400 obese patients in Massachusetts were prescribed medications such as Wegovy and Zepbound in 2024, a 255 percent increase from 2023, according to a Globe analysis of insurance claims ...

This move could force Novo Nordisk to slash the costs of its top drugs. The company should still ... Lilly's type 2 diabetes drug Mounjaro and obesity drug Zepbound aren't eligible for Medicare ...

Though people have shared personal stories of the medications’ sometimes surprising side effects, such as pregnancy, and individual studies ... Mounjaro and Zepbound, may change a person ...

citing slower-than-expected growth in sales of its diabetes and weight-loss drugs. “While the U.S. incretin market grew 45% compared to the same quarter last year, our previous guidance had ...